Answers are grounded in this paper and cite their sources.
Clinical pharmacology study observes the pharmacokinetics of iptacopan across hepatic impairment, highlighting safety considerations for factor b inhibition.
Iptacopan (LNP023) is an oral, first-in-class, low molecular weight inhibitor of Factor B in clinical development for the treatment of diseases associated with activation of the alternative complement pathway. Phase 3 studies of iptacopan are ongoing in paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis, IgA nephropathy, and atypical hemolytic uremic syndrome. Previous studies indicated the liver as the primary organ of iptacopan elimination, necessitating this study.
No takes yet. Share an insight, caveat, or question.
Schmouder et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: